MA32175B1 - Oxadiazoanthracènes pour le traitement du diabète - Google Patents

Oxadiazoanthracènes pour le traitement du diabète

Info

Publication number
MA32175B1
MA32175B1 MA33212A MA33212A MA32175B1 MA 32175 B1 MA32175 B1 MA 32175B1 MA 33212 A MA33212 A MA 33212A MA 33212 A MA33212 A MA 33212A MA 32175 B1 MA32175 B1 MA 32175B1
Authority
MA
Morocco
Prior art keywords
derivatives
diabetes
treatment
oxadiazo
oxadiazoanthracenes
Prior art date
Application number
MA33212A
Other languages
Arabic (ar)
English (en)
Inventor
Adnan M M Mjalli
Dharma Rao Polisetti
Thomas Scott Yokum
Kalpathy Santhosh
Mustafa Guzel
Christopher Behme
Stephen Thomas Davis
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of MA32175B1 publication Critical patent/MA32175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des dérivés de l'oxadiazoanthracène de formule (i) dans laquelle a, b, c, r, r1, r2, r3, r4 et r5 sont tels que décrits dans la description, des compositions pharmaceutiques comprenant les dérivés de l'oxadiazoanthracène, l'utilisation des dérivés de l'oxadiazoanthracène pour la préparation de compositions pharmaceutiques, des procédés de leur utilisation pour le traitement et/ou la prévention de maladies et de troubles tels que le diabète et des intermédiaires utiles pour la préparation des dérivés de l'oxadiazoanthracène de formule (i).
MA33212A 2008-03-07 2010-09-30 Oxadiazoanthracènes pour le traitement du diabète MA32175B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (fr) 2008-03-07 2009-03-06 Oxadiazoanthracènes pour le traitement du diabète

Publications (1)

Publication Number Publication Date
MA32175B1 true MA32175B1 (fr) 2011-03-01

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33212A MA32175B1 (fr) 2008-03-07 2010-09-30 Oxadiazoanthracènes pour le traitement du diabète

Country Status (17)

Country Link
US (7) US7727983B2 (fr)
EP (1) EP2262364B1 (fr)
JP (1) JP5382952B2 (fr)
KR (1) KR101616737B1 (fr)
CN (1) CN101959405B (fr)
AU (1) AU2009221722B2 (fr)
BR (1) BRPI0910282A2 (fr)
CA (1) CA2716664C (fr)
DK (1) DK2262364T3 (fr)
EA (1) EA018225B1 (fr)
ES (1) ES2567451T3 (fr)
IL (1) IL207570A (fr)
MA (1) MA32175B1 (fr)
MX (1) MX2010009752A (fr)
NZ (1) NZ587343A (fr)
WO (1) WO2009111700A2 (fr)
ZA (1) ZA201006367B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
MX2011010347A (es) * 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
WO2012096824A1 (fr) * 2011-01-12 2012-07-19 Transtech Pharma, Inc. Dérivés d'acide phénylglyoxylique et leur préparation et utilisation
PH12013501557A1 (en) 2011-02-08 2019-06-03 Pfizer Glucagon receptor modulator
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2854526B1 (fr) * 2012-03-22 2018-04-25 vTv Therapeutics LLC Sels de tris(hydroxyméthyl)aminométhane d'un agoniste de glp1r à petite molécule et compositions pharmaceutiques et utilisations de ces sels
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
SG10201704716XA (en) * 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
CN107074820B (zh) * 2014-07-25 2021-05-18 赛尔基因第二国际有限公司 Glp-1受体调节剂
EP3273981B1 (fr) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Procédé et composition pharmaceutique pour une utilisation dans le traitement du diabète
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (fr) * 2017-11-22 2019-05-31 第一三共株式会社 Composé tricyclique condensé
WO2019217165A1 (fr) 2018-05-08 2019-11-14 Vtv Therapeutics Llc Utilisations thérapeutiques d'agonistes de glp1r
EA202191432A1 (ru) 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
EP4130005A4 (fr) 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Forme cristalline a d'antagoniste du récepteur glp-1 et son procédé de préparation
CN115315426B (zh) 2020-04-01 2023-12-12 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN115667219B (zh) * 2020-05-28 2024-11-15 杭州中美华东制药有限公司 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
WO2021238964A1 (fr) * 2020-05-28 2021-12-02 杭州中美华东制药有限公司 Procédé de préparation d'une base libre d'agoniste du récepteur glp-1
JP7812052B2 (ja) 2020-09-01 2026-02-09 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
CN116348464B (zh) 2020-10-12 2026-06-16 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
US12516041B2 (en) 2020-10-14 2026-01-06 Qilu Regor Therapeutics Inc. Crystal forms of GLP-1R agonists and uses thereof
EP4247804A1 (fr) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Composés modulateurs de glp-1r polyhétérocycliques
WO2022111624A1 (fr) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale
CN116940561B (zh) 2021-03-22 2026-08-11 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
EP4317145A4 (fr) 2021-03-24 2025-03-12 Shionogi & Co., Ltd Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné
LT4271672T (lt) 2021-04-21 2026-03-10 Gilead Sciences, Inc. Karboksibenzimidazolo junginiai, moduliuojantys glp-1r
WO2022262615A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Composé anthracène, son procédé de préparation et son utilisation médicale
CN117098758A (zh) 2021-06-24 2023-11-21 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
EP4777197A2 (fr) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Agoniste de glp-1r et méthode thérapeutique associée
WO2025109387A1 (fr) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Agoniste de glp-1r et son procédé thérapeutique
AU2025207498A1 (en) 2024-01-09 2026-07-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Glp-1r agonist pharmaceutical composition and use thereof
WO2025158275A1 (fr) 2024-01-24 2025-07-31 Pfizer Inc. Polythérapie utilisant des composés antagonistes du récepteur du polypeptide insulinotrope glucose-dépendant et des composés agonistes du récepteur glp-1
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd 1,4−ベンゾオキサジン誘導体,その製造法およびそれを含有する医薬用組成物
EP0233728A1 (fr) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzoxazine, leur préparation et leur application
AU726450B2 (en) * 1995-10-06 2000-11-09 Ligand Pharmaceuticals Incorporated Dimer-selective RXR modulators and methods for their use
AU3033500A (en) * 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
MXPA02005528A (es) * 1999-12-03 2002-09-02 Kyoto Pharma Ind Compuestos heterociclicos sus sales y uso medicinal.
EP1125925A1 (fr) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Dérivés amines pour le traitement de l'apoptose
US20050222036A1 (en) * 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
RU2345985C2 (ru) * 2003-03-26 2009-02-10 Актелион Фармасьютиклз Лтд. Производные тетрагидроизохинолилацетамида в качестве антагонистов орексинового рецептора
EA018225B1 (ru) * 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
WO2011156655A2 (fr) 2010-06-09 2011-12-15 Receptos, Inc. Nouveaux stabilisants et modulateurs de récepteur glp-1

Also Published As

Publication number Publication date
US20140187769A1 (en) 2014-07-03
AU2009221722B2 (en) 2014-12-18
US8524708B2 (en) 2013-09-03
US20110039837A1 (en) 2011-02-17
MX2010009752A (es) 2010-09-30
US8703766B2 (en) 2014-04-22
HK1148435A1 (en) 2011-09-09
KR20100131455A (ko) 2010-12-15
WO2009111700A3 (fr) 2010-03-04
IL207570A0 (en) 2010-12-30
JP2011513431A (ja) 2011-04-28
US20100324033A1 (en) 2010-12-23
US20150087640A1 (en) 2015-03-26
EA201071045A1 (ru) 2011-02-28
CA2716664A1 (fr) 2009-09-11
US9120813B2 (en) 2015-09-01
WO2009111700A2 (fr) 2009-09-11
EA018225B1 (ru) 2013-06-28
DK2262364T3 (en) 2016-03-21
EP2262364A4 (fr) 2012-04-04
ES2567451T3 (es) 2016-04-22
CN101959405B (zh) 2014-07-02
US8933222B2 (en) 2015-01-13
KR101616737B1 (ko) 2016-05-02
US20090306063A1 (en) 2009-12-10
AU2009221722A1 (en) 2009-09-11
US7790714B2 (en) 2010-09-07
US7727983B2 (en) 2010-06-01
BRPI0910282A2 (pt) 2015-09-01
ZA201006367B (en) 2011-05-25
CN101959405A (zh) 2011-01-26
EP2262364A2 (fr) 2010-12-22
US20130317015A1 (en) 2013-11-28
JP5382952B2 (ja) 2014-01-08
US20100197677A1 (en) 2010-08-05
CA2716664C (fr) 2016-10-11
IL207570A (en) 2014-03-31
EP2262364B1 (fr) 2016-03-02
NZ587343A (en) 2012-05-25
US7906507B2 (en) 2011-03-15

Similar Documents

Publication Publication Date Title
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
MA34916B1 (fr) Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
EA201200794A1 (ru) Триазолопиридины
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
NO20090979L (no) (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38